XML 66 R41.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions - Adapt Narrative (Details)
$ / shares in Units, $ in Millions
9 Months Ended 12 Months Ended
Oct. 15, 2018
USD ($)
employee
$ / shares
shares
Sep. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Business Acquisition [Line Items]      
Contingent consideration   $ 14.5 $ 54.4
Goodwill   $ 268.6 $ 259.7
Maximum      
Business Acquisition [Line Items]      
Amortization period of intangible asset   22 years 22 years
Adapt Pharma      
Business Acquisition [Line Items]      
Number of employees | employee 50    
Common stock issued for acquisition (in shares) | shares 733,309    
Share price (in dollars per share) | $ / shares $ 60.44    
Consideration transferred, equity interests issued and issuable $ 44.3    
Equity $ 37.7    
Lock-up period for adjustment of fair value 2 years    
Fair value of contingent purchase consideration $ 48.0 $ 58.6  
Acquired intangible asset $ 534.0    
Amortization period of intangible asset 15 years    
Present value, discount rate 10.50%    
Acquired in-process research and development $ 41.0    
Goodwill $ 148.0    
Adapt Pharma | IPR&D      
Business Acquisition [Line Items]      
Present value, discount rate 11.00%    
Adapt Pharma | Previously Reported      
Business Acquisition [Line Items]      
Acquired intangible asset $ 534.0    
Goodwill 149.0    
Adapt Pharma | Previously Reported | IPR&D      
Business Acquisition [Line Items]      
Acquired in-process research and development 41.0    
Adapt Pharma | Maximum      
Business Acquisition [Line Items]      
Contingent consideration $ 100.0